Activity Of Bortezomib In Combination With Dexamethasone In 18 Patients With Untreated Multiple Myeloma

Objective:To evaluate the safety and activity of Bortezomib in combination with Dexamethasone in de nove Multiple Myeloma.Method:Eighteen de nove MM patients received treatment of Bortezomib combined with dexamethasone between December of 2006 to February of 2009. All patients received at least one cycle.Result:Four patients(22.2%) got complete response (CR) or very good complete response (VGPR),11 patients(61.1%) got partial response(PR), one patient (5.6%) got minute response (MR),2 patients (11.1%)were in stable condition. The overall response rate (CR+VGPR+PR) was 83.3%. Infection, anemia and renal insufficiency were improved in all patients. The drug-related side-effects included hematological toxicity 7/18 (1 patient was stage I,4 patients was stage II and 2 patients was stage III), peripheral sensory neuropathy 10/18 (3 patients was stage I,2 patients was stage,1 patients was stage III and,4 patients was stageâ…£, fatigue 4/18, infection9/18, herpes zster virus(HZV) infection 4/18, pulmonary infection 6/18, constipation 3/18, blockage of the intestine 2/18. But the all adverse reaction was relieved after drug withdrawal.Conclusion:The overall response rate of Bortezomib in combination with Dexamethasone for untreated Multiple Myeloma in our study is 80%. As the adverse effects of the regimen was mild, all patient were well tolerated.